FDA Approves Alhemo for Patients with Hemophilia

Routine prophylaxis to prevent or reduce bleeding

For Patients with Hemophilia A or B with Inhibitors

The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:

  • Hemophilia A with factor VIII inhibitors, or
  • Hemophilia B with factor IX inhibitors.

What It Is

  • Alhemo is a subcutaneous (under the skin) injection, taken daily.
  • It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.

Effectiveness

  • In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
  • Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.

Safety Info

  • Most common side effects: Injection site reactions and hives.
  • May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
  • Not recommended for patients with serious allergies to the drug or its ingredients.

Special FDA Designations

  • Priority Review
  • Orphan Drug status (for rare conditions)

Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.

More novel drug approvals.

Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.

The 30-Year Consequences of Faulty Supplement Legislation

How a 1994 Law Created Today’s Dietary Supplement Crisis   In light of the current moringa contamination recalls affecting national retailers and dozens of downstream manufacturers, many consumers are asking the same question: How did this happen?  The answer leads us...

Invisible Outbreak of Contaminated Supplement Ingredients

Contaminated Products Distributed Nationwide  How a contaminated Moringa shipment was spread across the U.S. supplement market, and why there were no additional recalls.  Sam’s Club announced a recall of its Member’s Mark Super Greens powder in late October 2025 due...

Organic Moringa Powder Recalled for Salmonella Contamination

On November 12, organic moringa powder importer and packager Africa Imports issued a recall notice for its products dating back to June 5. The recall notice was published on the FDA website. Following are details of the recall. Who Issued the Recall Africa Imports...